---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Executive summary: Disease burden"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Disease burden. Topics: Summary: population, risk, and disease course; Summary: economic burden and current treatment. 2 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary/disease-burden"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of APOL1-mediated kidney disease

<a id="topic-1.1.1-1"></a>

### Summary: population, risk, and disease course

APOL1-mediated kidney disease (AMKD) occurs in people with two APOL1 risk variants (G1 and G2) and affects people of African ancestry. Approximately 13% of Black individuals in the US, “more than 5 million people”, have a high-risk APOL1 genotype. Penetrance is incomplete: approximately 15% to 20% of African American individuals with two risk alleles develop CKD, and the lifetime risk of ESKD has been estimated at 15% to 30%. A Delphi consensus panel estimated that “up to 3% of the Black population will be affected”. Vertex estimates that AMKD affects approximately 150,000 people in the U.S. and Europe; no peer-reviewed count of people with AMKD in the U.S. or Europe was identified.

In the Atherosclerosis Risk in Communities study, carrying two risk alleles was associated with a 1.88-fold increased risk of ESRD compared with zero or one risk allele. A Vertex-sponsored testing page states that AMKD patients “progress to dialysis nine to 12 years earlier” than CKD patients of African ancestry with zero or one risk variant. In 2023, kidney failure was over four times more common among Black people than among White people in the United States.

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/); [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/); [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm); [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/); [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping); [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence); [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-1.1.1-2"></a>

### Summary: economic burden and current treatment

No cost or resource-use study specific to AMKD was identified. In the United States, total Medicare costs for people with ESRD reached $55.3 billion in 2023, and the yearly cost per person with fee-for-service coverage and CKD was $31,176 in 2023. No therapy directed at AMKD is approved; the KDIGO 2025 controversies conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, APOL1 status did not interact with the randomized blood-pressure goal or antihypertensive drug. In a real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5, 35.7% had a RAAS inhibitor fill or administration, and 10.5% had an SGLT2 inhibitor fill or administration.

Source: [USRDS Annual Data Report, ESRD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd); [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd); [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/); [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/); [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf); [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
